By Tom Salemi
Antony Koblish didn't flinch. The CEO of Orthovita Inc. was laying out his complaints about the results of two...
Orthovita had spent the past eight years building up a small commercial pipeline while it ran its flagship bone augmentation material Cortoss through years of a demanding clinical trial. But two months after the FDA approved the product, the company had to clear another unforeseen hurdle: two controversial clinical trials.
By Tom Salemi
Antony Koblish didn't flinch. The CEO of Orthovita Inc. was laying out his complaints about the results of two...